Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 547Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 332Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 260Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 203Carcinoma, Hepatocellular 196Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 132Glioblastoma 131Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 124Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

toripalimab 2zanidatamab 1tislelizumab 1disitamab vedotin 1Probiotics 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Muscle Invasive Bladder Cancer (MIBC) × 1 year × Clear all
NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07296705 2025-12-22

HARBOR

Fujian Medical University Union Hospital

Phase 2 Recruiting
25 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT07201675 2025-10-01

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting
59 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡